Quantification of Two Fluorophores’ Concentration Ratio in a Mice Model in Preparation for a Proposed Method for Early Detection of Alzheimer’s Disease
Source abstract
Abstract
Many biomedical applications require concentration measurements of biological compounds, which may be achieved using targeted fluorescent probes. It has been shown that the ratio between amyloid-Beta and tau protein in the cerebrospinal fluid (CSF) is a good indicator of incipient Alzheimer’s disease (AD). We have previously proposed a method that can accurately estimate the concentration ratio of these two proteins without the need to collect CSF samples: Fluorescent probes are injected to the blood and bind to the CSF biomarkers. A miniature needle with an optical fiber excites the fluorescent probes and collects the fluorescence emission. The concentration ratio between the proteins is estimated, and used for diagnosis of incipient AD. We present here the results of the method’s concentration ratio estimation during trials performed on mice. Miniature tubes containing two fluorescent probes in several concentration ratios were implanted in two locations in the mice: subcutaneously, and deeper in the abdomen. The fluorescent probes were excited and the fluorescence intensity was measured. The concentration ratios were estimated from the fluorescence intensities with an average error of less than 20%. This study is a step towards the demonstration of the method in in vivo studies in mice with markers in the bloodstream/CSF.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Alzheimer's disease research and treatments · Optical Imaging and Spectroscopy Techniques · Dementia and Cognitive Impairment Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
Department of Electrical and Computer Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
Funding
Tel-Aviv University-Herczeg Institute on Aging
References (36)
Show source-provided references
1. Alzheimer’s Association (2017). 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. J. Alzheimers Assoc., 13, 325–373.10.1016/j.jalz.2017.02.001 ↗
2. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects10.1002/ana.21610 ↗
3. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study10.1016/S1474-4422(06)70355-6 ↗
4. Cerebrospinal Fluid Levels of {beta}-Amyloid 1–42, but Not of Tau, Are Fully Changed Already 5 to 10 Years before the Onset of Alzheimer Dementia10.1001/archgenpsychiatry.2011.155 ↗
5. Cerebrospinal fluid levels of total tau, phospho tau and A 42 predicts development of Alzheimer’s disease in patients with mild cognitive impairment10.1034/j.1600-0404.107.s179.9.x ↗
6. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment10.1001/jama.2009.1064 ↗
7. Lumbar puncture: Anatomical review of a clinical skill10.1002/ca.10250 ↗
8. Inverse method 3-D reconstruction of localized in vivo fluorescence-Application to Sjogren syndrome10.1109/2944.796313 ↗
9. Three-dimensional localization of fluorescent masses deeply embedded in tissue10.1088/0031-9155/47/22/311 ↗
10. In vivo quantitative three-dimensional localization of tumor labeled with exogenous specific fluorescence markers10.1364/AO.42.003073 ↗
11. Quantitative optical imaging of the pharmacokinetics of fluorescent-specific antibodies to tumor markers through tissuelike turbid media10.1364/OL.29.000742 ↗
12. Localization and quantification of fluorescent inclusions embedded in a turbid medium10.1088/0031-9155/50/10/009 ↗
13. Analytical method for the fast time-domain reconstruction of fluorescent inclusions in vitro and in vivo10.1016/j.bpj.2009.10.008 ↗
14. In vivo simultaneous monitoring of two fluorophores with lifetime contrast using a full-field time domain system10.1364/AO.48.000D74 ↗
15. Validation of in vivo fluorochrome concentrations measured using fluorescence molecular tomography10.1117/1.1993427 ↗
16. Three-dimensional fluorescence enhanced optical tomography using referenced frequency-domain photon migration measurements at emission and excitation wavelengths10.1364/JOSAA.19.000759 ↗
17. Three-dimensional fluorescence lifetime tomography10.1118/1.1861160 ↗
18. Separately reconstructing the structural and functional parameters of a fluorescent inclusion embedded in a turbid medium10.1364/OE.14.007172 ↗
19. Radiative transport-based frequency-domain fluorescence tomography10.1088/0031-9155/53/8/005 ↗
20. Lifetime-based tomographic multiplexing10.1117/1.3469797 ↗
21. Accuracy of fluorescent tomography in the presence of heterogeneities: Study of the normalized Born ratio10.1109/TMI.2005.857213 ↗
22. Quantification of the hematoporphyrin derivative by fluorescence measurementusing dual-wavelength excitation anddual-wavelength detection10.1364/AO.32.000541 ↗
23. Smart optical probes for near-infrared fluorescence imaging of Alzheimer’s disease pathology10.1007/s00259-007-0708-7 ↗
24. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe10.1038/nbt1085 ↗
25. Design and Synthesis of Curcumin Analogues for in Vivo Fluorescence Imaging and Inhibiting Copper-Induced Cross-Linking of Amyloid Beta Species in Alzheimer’s Disease10.1021/ja405239v ↗
26. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-26510.3233/JAD-2010-100270 ↗
27. Efficient Near-Infrared in Vivo Imaging of Amyoid-β Deposits in Alzheimer’s Disease Mouse Models10.3233/JAD-2012-112168 ↗
28. Smart Near-Infrared Fluorescence Probes with Donor–Acceptor Structure for in Vivo Detection of β-Amyloid Deposits10.1021/ja4052922 ↗
29. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls10.1016/j.neuron.2013.07.037 ↗
30. Alzheimer’s disease imaging with a novel Tau targeted near infrared ratiometric probe
31. Fluorescent probes concentration estimation in vitro and ex vivo as a model for early detection of Alzheimer’s disease10.1117/1.JBO.19.12.127007 ↗
32. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits10.1021/ja9047043 ↗
33. A design for a stable and reproducible phantom for use in near infra-red imaging and spectroscopy10.1088/0031-9155/38/6/015 ↗
34. Optical properties of biological tissues: A review10.1088/0031-9155/58/11/R37 ↗
35. Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-Targeted Approaches10.3389/fneur.2015.00256 ↗
36. Exploring Biomarkers for Alzheimer’s Disease